Gland Pharma Limited vs Ajanta Pharma Limited
An objective side-by-side of GLAND and AJANTPHARM, both in Pharmaceuticals - Indian - Formulations: valuation, profitability, growth, balance sheet, ownership and share-price performance. Where one number is clearly better on its own terms (lower P/E, higher ROE), it is shaded. That is a description, not a recommendation.
Prices as of 2026-11-05 close
Latest results: GLAND Jun 2026 · AJANTPHARM Sep 2026
At a glance
- Gland Pharma Limited is the larger company by market value, about 1.3 times the size of Ajanta Pharma Limited.
- On trailing earnings, Ajanta Pharma Limited trades at the lower P/E (32.5 against 46.0).
- Ajanta Pharma Limited earns the higher return on equity (27.9% against 10.9%).
- Over three years Ajanta Pharma Limited has grown profits faster (21% a year against 8%).
- Over the past year the share prices returned +65.0% (GLAND) and +33.0% (AJANTPHARM).
| Metric | Gland Pharma GLAND |
Ajanta Pharma AJANTPHARM |
|---|---|---|
| Size and price | ||
| Market cap | ₹51,899 Cr | ₹41,013 Cr |
| Share price | ₹3,145.20 | ₹3,282.10 |
| Valuation | ||
| P/E | 45.96 | 32.47 |
| P/B | 5.01 | 9.06 |
| EV/EBITDA | 29.80 | 24.47 |
| PEG | 5.75 | 1.55 |
| Dividend yield | 0.6% | 0.9% |
| Profitability | ||
| ROE | 10.9% | 27.9% |
| ROCE | 15.0% | 32.0% |
| Operating margin | 26.0% | 27.1% |
| Sales (TTM) | ₹6,726 Cr | ₹6,217 Cr |
| Net profit (TTM) | ₹1,129 Cr | ₹1,263 Cr |
| Growth | ||
| Latest quarter sales YoY | +19.6% | +32.5% |
| Latest quarter profit YoY | +47.1% | +49.2% |
| Sales CAGR 3Y | +21.0% | +13.0% |
| Profit CAGR 3Y | +8.0% | +21.0% |
| Sales CAGR 5Y | +13.0% | +14.0% |
| Profit CAGR 5Y | +1.0% | +10.0% |
| Financial strength | ||
| Debt/Equity | 0.03 | 0.06 |
| Interest cover | 36.26 | 77.57 |
| Ownership | ||
| Promoter holding | 45.8% | 63.5% |
| Promoter change (4 qtrs) | -6.08 pp | -2.78 pp |
| Price performance | ||
| Return 1M | +4.63% | -8.15% |
| Return 3M | +23.58% | -4.52% |
| Return 1Y | +65.03% | +32.95% |
| Return YTD | +82.65% | +18.53% |
| Technical condition | ||
| Technical score | 78 | 28 |
| RS rating (1-99) | 94.00 | 75.00 |
| % vs 200-DMA | +36.60% | +3.35% |
| RSI (14) | 61.55 | 40.08 |
| % from 52-week high | -1.98% | -13.54% |
